Results 41 to 50 of about 18,898 (135)

Feasibility, Adherence and Efficacy of Liraglutide Treatment in a Sample of Individuals With Mood Disorders and Obesity

Frontiers in Psychiatry, 2019
Background: Liraglutide is a once-daily injectable medication approved for the treatment of obesity. Hereby we report the feasibility, adherence and efficacy of liraglutide treatment in a sample of individuals with mood disorders and obesity.Methods and ...
Alessandro Cuomo, Simone Bolognesi, Arianna Goracci, Cristina Ciuoli, Bruno Beccarini Crescenzi, Giuseppe Maina, Gianluca Rosso, Edvige Facchi, Carla Maccora, Nicola Giordano, Valeria Verdino, Andrea Fagiolini   +11 more
doaj   +1 more source

Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

Journal of Diabetes Research, 2015
Aims. Glucagon-like peptide-1 (GLP-1) analog promotes insulin secretion by acting on pancreatic β-cells. This antihyperglycemic treatment for type 2 diabetes mellitus (DM) has attracted increased clinical attention not only for its antihyperglycemic ...
Hideaki Jinnouchi, Seigo Sugiyama, Akira Yoshida, Kunio Hieshima, Noboru Kurinami, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara, Kunihiko Matsui, Tomio Jinnouchi   +9 more
doaj   +1 more source

Liraglutide enhances the effect of checkpoint blockade in lung and liver cancers through the inhibition of neutrophil extracellular traps

FEBS Open Bio
Glucagon‐like peptide‐1 (GLP‐1) regulates glycemic excursions by augmenting insulin production and inhibiting glucagon secretion. Liraglutide, a long‐acting GLP‐1 analog, can improve glycemic control for treating type 2 diabetes and prevent neutrophil ...
Duo Chen, Hongxin Liang, Luyu Huang, Haiyu Zhou, Zheng Wang   +4 more
doaj   +1 more source

Liraglutide-Induced Liver Injury: A Case Report and Review

Case Reports in Gastroenterology
Introduction: Glucagon-like peptide-1 receptor agonists such as liraglutide have revolutionized the management of type 2 diabetes and obesity. Case Presentation: We present a case of a 30-year-old woman who developed drug-induced liver injury (
Mark Lai, Patrick Hosking, Rohit Sawhney, Amanda Nicoll   +3 more
doaj   +1 more source

Liraglutide Attenuates Disease Severity in Experimental Autoimmune Encephalomyelitis by Modulating Splenic T Helper Cell Subsets

Brain and Behavior
Objective To investigate the therapeutic effects of liraglutide, a glucagon‐like peptide‐1 receptor agonist, on clinical progression and splenic T‐cell subsets in experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis ...
Shuang Song, Bin Li, Ruoyi Guo, Yi Zhou, Yumei Xue, Li Guo   +5 more
doaj   +1 more source

Liraglutide Inhibits Endothelial-to-Mesenchymal Transition and Attenuates Neointima Formation after Endovascular Injury in Streptozotocin-Induced Diabetic Mice

Cells, 2019
Hyperglycaemia causes endothelial dysfunction, which is the initial process in the development of diabetic vascular complications. Upon injury, endothelial cells undergo an endothelial-to-mesenchymal transition (EndMT), lose their specific marker, and ...
Tzu-Hsien Tsai, Chien-Ho Lee, Cheng-I Cheng, Yen-Nan Fang, Sheng-Ying Chung, Shyh-Ming Chen, Cheng-Jei Lin, Chiung-Jen Wu, Chi-Ling Hang, Wei-Yu Chen   +9 more
doaj   +1 more source

A diabetic patient increased premature ventricular contractions after using liraglutide: a case report

Frontiers in Cardiovascular Medicine
The common adverse reactions of liraglutide are hypoglycemia and gastrointestinal reactions. This case reports a patient with type 2 diabetes mellitus who had an increase in ventricular premature beats after using liraglutide and a decrease in ...
Lilan Huang, He Yu, Ying Fang
doaj   +1 more source

Liraglutide and calcitonin [PDF]

Journal of Diabetes, 2010
openaire   +2 more sources

Potential of liraglutide in the treatment of patients with type 2 diabetes

Vascular Health and Risk Management, 2009
Carolyn F DeaconDepartment of Biomedical Sciences, Panum Institute, DK-2200 Copenhagen N, DenmarkAbstract: Liraglutide is a long-acting analog of GLP-1, being developed by Novo Nordisk and currently undergoing regulatory review for the treatment of type ...
Carolyn F Deacon
doaj  

Liraglutide alleviates sepsis-associated encephalopathy via attenuating neuronal damage, glial cell activation and mitochondrial dysfunction in a mouse model of sepsis

European Journal of Medical Research
Objective To explore the relevant mechanisms and principles by which liraglutide alleviates sepsis-associated encephalopathy (SAE) through reducing neuronal injury, glial cell activation and mitochondrial dysfunction.
Xiaoming Li, Jun Wang, Rongji Zhang, Haoran He, Linjue Wang, Yuliang Wang, Hongyu Yi   +6 more
doaj   +1 more source